The MHRA provides an update to previous guidance on the management of patients treated with the recalled Endologix Nellix EVAS System to reflect revised recommendations. All implanted patients in the UK with this device should be identified and appropriate action taken.
Similar Posts
Clinical trials for medicines: expert advice
Clinical trial applications that need expert advice from a specialist group or committee.
UK clinical trial approval times twice as fast with AI and reforms
Patients receive earlier access to life-saving treatments as UK trial approval times cut in half from 91 to just 41 days.
Class 2 Medicines Recall: Depo-Medrone 80 mg in 2 mL, Maxearn Limited EL(25)A/29
A batch of Depo-Medrone has been released to the market with an error. The vial over label incorrectly states that the total vial content is 40 mg in 1 mL, when the correct total vial content is 80mg in 2 mL (with a concentration of 40mg/ml of methylprednisolone acetate).
Government cuts red tape to revolutionise public services with cutting-edge tech
The government has announced it is slashing the red tape that holds back groundbreaking innovations from coming to market.
Device specific vigilance guidance: Cardiac Implantable Electronic Devices (CIEDs)
Guidance for manufacturers of cardiac implantable electronic devices and their leads. It outlines specific scenarios that should be considered when determining if an incident is reportable.
Research: Report of The Commission on Human Medicines Isotretinoin Implementation Advisory Expert Working Group
Report of Isotretinoin Implementation Advisory Expert Working Group regarding recommendations to strengthen the safe use of isotretinoin, the acne medicine commonly known by brand names Roaccutane and Reticutan.